chlorothiazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diuretics, chlorothiazide derivatives 609 58-94-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorothiazide
  • chlorothiazide sodium
A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
  • Molecular weight: 295.71
  • Formula: C7H6ClN3O4S2
  • CLOGP: -0.29
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 118.69
  • ALOGS: -2.85
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.70 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 92 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 112.60 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 13 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.154 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.852 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.261 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.459 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 40.950 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 19.060 % High 1
herg hERG pIC50 4.027 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.213 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.105 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 31.620 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 51
kinase-selectivity-class GRK2,MAP2K6,PDK1,PDK2,TEK,UHMK1,ZAP70 7
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.052 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.628 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.861 High 1
mppb Mouse plasma protein binding (% unbound) 41.170 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.385 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 31.370 % High 1
rat-kpuu-brain Rat brain Kpuu 0.012 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.388 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.990 % High 1
rppb Rat plasma protein binding (% unbound) 20.410 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 950.605 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 4, 1958 FDA OAK PHARMS AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary vein stenosis 36.61 29.42 5 1134 92 90627216
Respiratory failure 36.24 29.42 21 1118 118397 90508911
Rhinovirus infection 34.20 29.42 9 1130 5954 90621354
Hypervolaemia 32.36 29.42 13 1126 32744 90594564
Heparin-induced thrombocytopenia 30.38 29.42 8 1131 5304 90622004

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary hypertension 45.71 26.89 20 1397 23549 42596369
Respiratory failure 45.45 26.89 36 1381 128096 42491822
Hyperparathyroidism secondary 41.05 26.89 10 1407 1832 42618086
Respiratory distress 32.18 26.89 19 1398 41801 42578117

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Respiratory failure 61.24 24.12 44 2263 215288 110371704
Respiratory distress 53.78 24.12 27 2280 68847 110518145
Hyperparathyroidism secondary 39.86 24.12 10 2297 3294 110583698
Pulmonary vein stenosis 38.87 24.12 6 2301 157 110586835
Pulmonary hypertension 38.32 24.12 20 2287 55200 110531792
Hospitalisation 37.91 24.12 28 2279 142465 110444527
Hypoxia 35.69 24.12 26 2281 129489 110457503
Pulmonary arterial hypertension 35.28 24.12 16 2291 32552 110554440
Hypervolaemia 31.72 24.12 17 2290 49443 110537549
Rhinovirus infection 31.08 24.12 11 2296 11778 110575214
Catheterisation cardiac 29.34 24.12 9 2298 6182 110580810
Oxygen saturation decreased 29.19 24.12 25 2282 156957 110430035
Cardiac arrest 28.08 24.12 27 2280 196726 110390266
Cardiac operation 25.41 24.12 8 2299 5987 110581005
Acute respiratory failure 25.12 24.12 17 2290 75243 110511749
Aspartate aminotransferase increased 24.82 24.12 23 2284 159913 110427079
Tracheitis 24.76 24.12 6 2301 1715 110585277
Heart disease congenital 24.48 24.12 5 2302 657 110586335

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03AA04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides, plain
ATC C03AB04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides and potassium in combination
ATC C03AH01 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, THIAZIDES
Thiazides, combinations with psycholeptics and/or analgesics
FDA CS M0471776 Thiazides
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175419 Thiazide Diuretic
CHEBI has role CHEBI:35498 diuretic
CHEBI has role CHEBI:35674 antihypertensive agent
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D045283 Natriuretic Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Related Drugs by ATC class:

C03AA Thiazides, plain 9 drugs
bendroflumethiazidecyclopenthiazidecyclothiazidehydrochlorothiazidehydroflumethiazidemebutizidemethylclothiazidepolythiazidetrichlormethiazide
C03AB Thiazides and potassium in combination 8 drugs
bendroflumethiazidecyclopenthiazidecyclothiazidehydrochlorothiazidehydroflumethiazidemethylclothiazidepolythiazidetrichlormethiazide
C03AH Thiazides, combinations with psycholeptics and/or analgesics 1 drug
hydroflumethiazide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Edema indication 267038008
Hypertensive urgency indication 443482000
Edema due to Nephrotic Syndrome indication
Edema due to Hepatic Cirrhosis indication
Hypertension with Left Ventricular Hypertrophy indication
Pulmonary Edema due to Chronic Heart Failure indication
Peripheral Edema due to Chronic Heart Failure indication
Nephrogenic diabetes insipidus off-label use 111395007 DOID:12387
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Suicidal thoughts contraindication 6471006
Psoriasis contraindication 9014002 DOID:8893
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Chronic disease of respiratory system contraindication 17097001
Metabolic acidosis, normal anion gap, acidifying salts contraindication 18104000
Jaundice contraindication 18165001
Cirrhosis of liver contraindication 19943007 DOID:5082
Secondary angle-closure glaucoma contraindication 21571006
Electroconvulsive therapy contraindication 23835007
Acute vomiting contraindication 23971007
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Obstruction of bile duct contraindication 30144000
Parkinsonism contraindication 32798002
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Sick sinus syndrome contraindication 36083008 DOID:13884
Acute hepatitis contraindication 37871000
Immunosuppression contraindication 38013005
Anaphylaxis contraindication 39579001
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Sinus bradycardia contraindication 49710005
Cough contraindication 49727002
Acidosis contraindication 51387008
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aortic valve stenosis contraindication 60573004 DOID:1712
Chronic bronchitis contraindication 63480004 DOID:6132
Ulcerative colitis contraindication 64766004 DOID:8577
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Benign intracranial hypertension contraindication 68267002 DOID:11459
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Oliguria contraindication 83128009
Epilepsy contraindication 84757009 DOID:1826
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Kidney stone contraindication 95570007
Disorder of connective tissue contraindication 105969002 DOID:65
Diabetic renal disease contraindication 127013003
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Angina pectoris contraindication 194828000
Partial atrioventricular block contraindication 195039008
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Acute hepatic failure contraindication 197270009
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Disorder of electrolytes contraindication 237840007
Lupus erythematosus and erythema multiforme-like syndrome contraindication 238926009
Rhabdomyolysis contraindication 240131006
Raynaud's phenomenon contraindication 266261006
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Pheochromocytoma contraindication 302835009
Hypertriglyceridemia contraindication 302870006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000
Surgical procedure contraindication 387713003
Peripheral arterial occlusive disease contraindication 399957001
Peripheral vascular disease contraindication 400047006
Severe diarrhea contraindication 409587002
Autoimmune hemolytic anemia contraindication 413603009 DOID:718
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Porphyria contraindication 418470004
Intraoperative floppy iris syndrome contraindication 418801006
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Azotemia contraindication 445009001
Smokes tobacco daily contraindication 449868002
Acute exacerbation of asthma contraindication 708038006
Severe Cerebrovascular Disease contraindication
Hemodialysis with High-Flux Membrane contraindication
Head and Neck Angioedema contraindication
First Degree Atrioventricular Heart Block contraindication
Intestinal Angioedema contraindication
Severe Aortic Valve Stenosis contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Congestive heart failure Indication
Dogs Renal edema Indication

🐶 Veterinary products

ProductApplicantIngredients
Diuril Tablet Boehringer lngelheim Animal Health USA Inc. 1
Diuril Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.53 acidic
pKa2 9.74 acidic
pKa3 4.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR A2 5.43 WOMBAT-PK CHEMBL
Carbonic anhydrase 2 Enzyme WOMBAT-PK
Carbonic anhydrase 1 Enzyme IC50 6.34 CHEMBL

External reference:

IDSource
4017731 VUID
N0000146099 NUI
D00519 KEGG_DRUG
7085-44-1 SECONDARY_CAS_RN
2396 RXNORM
C0008273 UMLSCUI
CHEBI:3640 CHEBI
CHEMBL842 ChEMBL_ID
DB00880 DRUGBANK_ID
CHEMBL1200616 ChEMBL_ID
D002740 MESH_DESCRIPTOR_UI
2720 PUBCHEM_CID
4835 IUPHAR_LIGAND_ID
636 INN_ID
77W477J15H UNII
169210 MMSL
3950 MMSL
4419 MMSL
4420 MMSL
d00190 MMSL
002292 NDDF
002293 NDDF
372782002 SNOMEDCT_US
5786005 SNOMEDCT_US
8252004 SNOMEDCT_US
4017731 VANDF
4017732 VANDF
77W477J15H INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorothiazide Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0517-1820 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
Chlorothiazide Sodium HUMAN PRESCRIPTION DRUG LABEL 1 17478-419 INJECTION 500 mg INTRAVENOUS NDA authorized generic 25 sections
chlorothiazide sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-305 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 25 sections
chlorothiazide sodium HUMAN PRESCRIPTION DRUG LABEL 1 25021-305 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 25 sections
CHLOROTHIAZIDE SODIUM Human Prescription Drug Label 1 47335-330 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 21 sections
Chlorothiazide HUMAN PRESCRIPTION DRUG LABEL 1 63323-658 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
Chlorothiazide HUMAN PRESCRIPTION DRUG LABEL 1 63323-658 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
Chlorothiazide HUMAN PRESCRIPTION DRUG LABEL 1 63323-658 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
DIURIL HUMAN PRESCRIPTION DRUG LABEL 1 65649-311 SUSPENSION 250 mg ORAL NDA 23 sections
Chlorothiazide sodium Human Prescription Drug Label 1 68083-614 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 19 sections
Sodium Diuril HUMAN PRESCRIPTION DRUG LABEL 1 76478-711 INJECTION 0.50 mg INTRAVENOUS NDA 24 sections